Business UpdateJun 11, 2026, 07:01 AM
Medifast's OPTAVIA Program Shows 98% Lean Mass Retention in Study
AI Summary
Medifast's OPTAVIA program highlighted its strong clinical evidence, based on peer-reviewed randomized controlled trials and gold-standard DXA body composition measurements. The company emphasized that its program achieved 98% lean mass retention and a 14% reduction in visceral fat at 16 weeks. Coach-supported clients also lost significantly more weight and fat compared to self-directed groups, positioning OPTAVIA as a scientifically rigorous option in the rapidly expanding weight loss market, valued at $31.07 billion in 2025 and projected to exceed $45 billion by 2030.
Key Highlights
- Weight loss and diet management market valued at $31.07 billion in 2025, projected to surpass $45 billion by 2030.
- OPTAVIA's Optimal Weight 5 & 1 Plan® retained 98% lean mass at 16 weeks in a randomized controlled trial.
- The OPTAVIA program achieved a 14% reduction in visceral fat at 16 weeks.
- Coach-supported OPTAVIA clients lost 10 times more weight and 17 times more fat than self-directed groups.
- The OPTAVIA trial reported a 92.3% completion rate across 198 participants over 16 weeks.
Price Impact
More from MED